Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.52 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991814 | 1.00 | TGFBR1 (0.52) | TGFBR1TGFBR2MAP3K20MAPK14PDE4B | |
| SCHEMBL19991796 | 0.94 | TGFBR1 (0.48) | TGFBR1TGFBR2MAP3K20MAPK14PRMT5 | |
| SCHEMBL29908594 | 0.94 | TGFBR1 (0.48) | TGFBR1TGFBR2MAP3K20MAPK14PRMT5 | |
| SCHEMBL29908590 | 0.83 | TGFBR1 (0.72) | TGFBR1TGFBR2MAP3K20 | |
| SCHEMBL18114959 | 0.83 | TGFBR1 (0.72) | TGFBR1TGFBR2MAP3K20 | |
| SCHEMBL18124015 | 0.82 | TGFBR1 (0.44) | TGFBR1TGFBR2MAP3K20MAPK14PRMT5 | |
| SCHEMBL29908612 | 0.82 | TGFBR1 (0.44) | TGFBR1TGFBR2MAP3K20MAPK14PRMT5 | |
| SCHEMBL18124173 | 0.81 | GSK3B (0.45) | TGFBR1TGFBR2MAP3K20MAPK14DYRK1A | |
| SCHEMBL29908580 | 0.81 | GSK3B (0.45) | TGFBR1TGFBR2MAP3K20MAPK14DYRK1A | |
| SCHEMBL18115046 | 0.81 | MAPK14 (0.42) | TGFBR1MAPK14PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885MAP3K20 1663/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885MAP3K20 1663/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885MAP3K20 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.